Cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer in South Africa.
Sarah Xinhui TanYoanna S PumpalovaAlexandra M RogersKishan BhattCandice-Lee HerbstPaul RuffAlfred I NeugutChin HurPublished in: Cancer medicine (2023)
Colon cancer incidence is increasing in low- and middle-income countries, including South Africa, where resource constraints can impact treatment decisions. This cost-effectiveness study evaluates three systemic adjuvant chemotherapy options, compared to surgery alone, for patients in South African public hospitals after surgical resection for high-risk stage II and stage III colon cancer. Doublet adjuvant chemotherapy (capecitabine and oxaliplatin) for 3 months is the cost-effective strategy and should be recommended in South Africa.
Keyphrases
- south africa
- hiv positive
- end stage renal disease
- healthcare
- chronic kidney disease
- ejection fraction
- newly diagnosed
- minimally invasive
- coronary artery bypass
- prognostic factors
- clinical trial
- randomized controlled trial
- squamous cell carcinoma
- men who have sex with men
- patient reported outcomes
- phase ii study
- percutaneous coronary intervention
- atrial fibrillation
- metastatic breast cancer
- patient reported